Bio­Marin says the FDA game clock now tick­ing on their block­buster hope­ful peg­valiase

Bio­Marin $BM­RN has tak­en a big step to­ward a fi­nal FDA de­ci­sion on its lat­est rare dis­ease drug to reach reg­u­la­tors. The agency

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.